Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
hepatitis B
Biotech
Altimmune bails on hepatitis B after phase 2 data disappoint
The drug candidate, which Altimmune was preparing for partnering, failed to meet the bar for further development in a phase 2 study.
Nick Paul Taylor
Mar 27, 2024 7:57am
Brii punts HIV, depression, lung programs to potential partners
Mar 22, 2024 11:34am
Roche grows hepatitis diagnostics roster with new immunoassays
Nov 27, 2023 10:26am
Hepatitis B drug developers chart slow progress, just like hep C
Nov 14, 2023 9:05am
Vaccitech reemerges as Barinthus with hep B data
Nov 10, 2023 9:30am
Arrowhead finds a new (old) partner for J&J hep B program: GSK
Oct 31, 2023 9:05am